Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Inflammatory Breast Cancer
Interventions: BIOLOGICAL: Bevacizumab|DRUG: Cyclophosphamide|DRUG: epirubicin hydrochloride|DRUG: fluorouracil|DRUG: Docetaxel|BIOLOGICAL: Trastuzumab
Sponsor: Association Tunisienne de lutte Contre le Cancer
Collaborators: Hoffmann-La Roche|Sanofi